Premium
Topiramate‐Induced Intractable Cough During Migraine Prophylaxis
Author(s) -
Maggioni Ferdinando,
Mampreso Edoardo,
Mainardi Federico,
Lisotto Carlo,
Malvindi Maria Lucia,
Zanchin Giorgio
Publication year - 2010
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/j.1526-4610.2009.01515.x
Subject(s) - topiramate , discontinuation , migraine , medicine , somnolence , anesthesia , valproic acid , adverse effect , ataxia , placebo , zonisamide , randomized controlled trial , pediatrics , epilepsy , psychiatry , alternative medicine , pathology
( Headache 2010;50:301‐304) Topiramate is a highly effective drug in migraine prophylaxis and is considered a first‐line treatment. The evidence for the efficacy of topiramate is based upon the results of several large, randomized, double‐blind, placebo‐controlled trials. Adverse events (AEs) are common and require discontinuation of the treatment in about 20‐25% of patients, but they are rarely severe. There are reviews regarding topiramate‐related AEs representing a large number of patients treated in controlled trials. The most common AEs are weight loss, dizziness, somnolence, abnormal thinking, fatigue, ataxia, confusion, paresthesias, impaired concentration, nervousness, amnesia, and language difficulties. The development of cough has never been reported as an AE during topiramate prophylaxis for migraine. We present 3 cases in which the prophylactic treatment for migraine with topiramate was discontinued due to the onset of primary intractable coughing.